Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread -- Ignore unavailable to you. Want to Upgrade?

To: westpacific who wrote (34767)	3/2/2001 12:09:34 AM
From: AD	Respond to of 49816

pritchettcartoons.com Friday? AD

To: westpacific who wrote (34767)	3/2/2001 12:11:39 AM
From: AD	Respond to of 49816

westpacific, Now that you have shown the decency stan asked for, I have one thing to say to you. I agree all the way. Still, a rally would be a nice change of pace ;-) AD

To: westpacific who wrote (34767)	3/2/2001 2:27:09 AM
From: JeanD	Respond to of 49816

Yuck ... you again? Quit acting like you're so "dead-on" with your picks West. I've been tracking this one you mentioned over on RB: Oops, don't look now but it's down 50%. Got a nice bounce today, but it was down even further than that. There are plenty of intelligent people on SI to pay attention to that post their thoughts on the market in an adult way. And that group of people doesn't include you. Go away and stop embarrassing yourself. By: westpacific $$$$ Reply To: 37613 by westpacific $$$$ Monday, 15 Jan 2001 at 1:32 PM EST Post # of 46855 RIGL - bios may benefit once the rally in technology dies. Avoid the bio tool makers and focus on drug discovery plays IMO. This one has some solid contracts already in place, great alliances, solid underwriters and a decent cash position per share. Recent coverage paints the picture: Rigel Pharmaceuticals, Inc. NASDAQ: RIGL/$10.00 Buy Michael King, Biopharmaceuticals “We are initiating research coverage of Rigel Pharmaceuticals with a Buy rating,” said King. “We believe Rigel has positioned itself as a leader in post-genomics drug discovery, with an advanced scientific platform and small molecule therapeutics portfolio that surpasses that of comparable early-stage drug discovery companies. We believe Rigel will be one of the few companies with a leading robust portfolio of validated drug targets capable of growing into multi-billion dollar pharmaceuticals.”